As the novel coronavirus and disease it causes, COVID-19, continues to spread, Access Accelerated is closely watching the outbreak and thinking of all those affected. We stand by the health workers and responders who are courageously addressing this evolving situation. We are proud to see Access Accelerated member companies rising to the challenge to support the global response.

This public health emergency underscores the importance of building resilient health systems. The outbreak of respiratory disease caused by the novel coronavirus demands strong health systems that can adapt to manage health crises, while continuing to address the ongoing health needs of the population.

The investment in infrastructure, policy and capacity needed to manage infectious diseases can also support the response to chronic non-communicable diseases, and ultimately will help people live better and healthier lives. Access Accelerated remains committed to uniting the private and public sectors to strengthen health systems in low- and middle-income countries.

Industry Contributions through Access Accelerated

Universal health coverage (UHC) has become an increasingly powerful common cause in global health as countries around the world seek to bring quality care to more of their populations, while protecting them from financial hardship.  UHC is a cornerstone of the United Nations (UN) Sustainable Development Goals (SDGs), and as a central priority in its current general program of work, the World Health Organization (WHO) has committed to achieving UHC for 1 billion people by 2023.

The Access Accelerated approach is anchored in growing global and local momentum to achieve UHC; effectively addressing NCDs is foundational to achieving UHC and crucial to realizing the SDGs. As the growing burden of NCDs continues to put pressure on local health systems’ ability to ensure its people can access equitable, high-quality and affordable health care, Access Accelerated is mobilizing the collective capacity of the biopharmaceutical industry and its partners to address this challenge through our NCD initiatives.

Read the full white paper to learn more

Japanese Companies – Six Cross Cutting Principles

As Japanese engagement in solving global health challenges increases, we asked Access member companies for their perspective on how to put our six cross-cutting principles into practice. These principles lay the foundation for effective design in public health programming, and for our Japanese member companies, are vital for articulating commitments and making an impact.Read More

In July 2019, the Boston University Access Observatory, an independently developed measurement framework that is separate from Access Accelerated, published its second annual report, “Establishing the Foundation for Shared Learning.” As the title suggests, the report underscores the efforts our member companies are making to demonstrate three of our cross-cutting principles in action: continuous learning, rigorous measurement and transparency.Read More

Access Accelerated in Action shares experiences from 19 member company NCD access programs implemented in collaboration with more than 50 cross-sector partners

GENEVA, SWITZERLAND – 20 May 2019 – Today, at a side event on the margins of the 72nd World Health Assembly, Access Accelerated, a global partnership of more than 20 biopharmaceutical companies, launched Access Accelerated in Action: Key Learnings in Program Design & Implementation. This resource is the first collective effort from Access Accelerated member companies to share insights from their NCD programs in low- and middle-income countries (LMICs). Access Accelerated in Action is an effort to enhance the impact of public-private partnerships to address the global NCD burden and strengthen health systems in support of Universal Health Coverage (UHC). Read More

Two global biopharmaceutical companies join effort to address the growing non-communicable disease burden in low- and middle-income countries

GENEVA, SWITZERLAND – Today, Ipsen and Servier, two global biopharmaceutical companies, joined Access Accelerated, an initiative aimed at advancing access to non-communicable disease (NCD) prevention, treatment and care in low- and middle income countries (LMICs). Together with partners from across the global biopharmaceutical sector, multilateral organizations and non-governmental organizations, Access Accelerated works toward a future where no one dies prematurely from treatable, preventable diseases.Read More

Access Accelerated returned to Kenya from 28 February to 1 March for the non-communicable diseases (NCDs) stakeholder meeting, “Redefining UHC – the Opportunity for NCDs,” co-hosted with the Ministry of Health and NCD Alliance Kenya in Naivasha. With representation from the Kenyan government across ministries and attendees that spanned civil society, representatives from 12 Access Accelerated member companies, people living with NCDs (PLWNCDs) and government officials from six African nations, the meeting provided a forum to reflect on progress made and recommit to increasing access to NCD treatment and care in the context of the country’s push toward Universal Health Coverage (UHC).
Read More